Chinese Journal of Dermatology ›› 2012, Vol. 45 ›› Issue (4): 293-295.

• Prologue • Previous Articles     Next Articles

Advances in the treatment of malignant melanoma

  

  • Received:2011-06-01 Revised:2011-08-10 Online:2012-04-15 Published:2012-03-30
  • Contact: peng liang E-mail:liangpeng0801@sina.com

Abstract:

Malignant melanoma is a highly malignant skin cancer, surgery is the primary treatment of hand, most of the early detection of early surgery can achieve good effect, dacarbazine is still the gold standard chemotherapy for melanoma, with efficiency of 10% to 25% The median survival of only 8 months, although the combined chemotherapy and bio-chemotherapy improved overall response rate, but failed to improve overall survival, once distant metastases is difficult to control, very poor prognosis. dacarbazine, such as temozolomide efficacy of combined targeted therapy is uncertain.

Key words: treatment

CLC Number: 

  • R730.26